Company intelligence / Profile preview

ICHORtec

Aachen, North Rhine-Westphalia, Germany

Ownership: Private
Development stage: Other

Overview

ICHORtec has developed and validated the ICHOR system, a molecular diagnostic platform for rapid, point-of-care COVID-19 detection (capable of RNA and antibody testing), and their Quantum FMB® technology offers highly precise, energy-based molecular detection with <3 minute results and >95% accuracy.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic
Industry: Molecular Diagnostics

Partnerships

Fraunhofer Institute for Molecular Biology and Applied Ecology IMEUniklinikum AachenJohns Hopkins University

Beyond the preview

Go deeper on ICHORtec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICHORtec.

Explore the full profile